Efficacy and safety of muraglitazar: a double-blind,24-week,dose-ranging study in patients with type 2 diabetes

Abstract

Muraglitazar is a dual (α/γ) PPAR activator. Dual receptor activation may improve glycaemic and lipid profiles in patients with type 2 diabetes mellitus.This randomised double-blind trial in 1,477 drug-naive patients with type 2 diabetes compared the efficacy and safety of muraglitazar (0.5, 1.5, 5, 10, and 20 mg) with pioglitazone (15 mg). Endpoints included changes in HbA_1C and plasma lipids, last observation carried forward over 24 weeks. At week 24, mean changes from baseline in HbA_1C ranged from —0.25% to —1.76% with muraglitazar (p≤0.0008, 0.5 mg versus each higher muraglitazar dose), compared with —0.57% with pioglitazone. At week 12, tri-glycerides decreased 4—41% with muraglitazar and 9% with pioglitazone. High-density lipoprotein cholesterol increased 6—23% with muraglitazar and 10% with pioglitazone. Oedema-related events occurred with muraglitazar in a dose-dependent incidence (range 9—40%), and at 14% with pioglitazone. Overall, muraglitazar produced simultaneous dose-dependent improvements in glycaemic and lipid parameters in drug-naive patients with type 2 diabetes mellitus.

Keywords

PPAR α/γ activator PPAR agonist type 2 diabetes oral antidiabetic therapy

References

Haffner, SM (1998) Management of dyslipidemia in adults with diabetes . Diabetes Care 21: 160-78.

Haffner, SM, American Diabetes Association. (2004) Dyslipidemia management in adults with diabetes. Diabetes Care 27: S68-S71.

Rubins, HB , Robins, SJ , Collins, D. , et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-18.

Berger, JP , Akiyama, TE , Meinke, PT (2005) PPARs: therapeutic targets for metabolic disease . Trends Pharmacol Sci 26: 244-51.

Boden, G. , Laakso, M. (2004) Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27: 2253-59.

Buse, JB , Rubin, CJ , Frederich, R. , et al. (2005) Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 27: 1181-95.

Kendall, DM , Rubin, CJ , Mohideen, P. , et al. (2006) Improvement of glycaemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29: 1016-23.

Rubin, CJ , Ledeine, J-M. , Fiedorek, FT (2008) Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. Diab Vasc Dis Res 5: 168-76.

Koch, G. , Gansky, S. (1996) Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 30: 523-34.

10.

Nesto, RW , Bell, D. , Bonow, RO , et al. (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256-63.

11.

Guan, Y. , Hao, C. , Cha, DR , et al. (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11: 861-66.